当前位置:首页 - 行情中心 - 赛托生物(300583) - 财务分析 - 现金流量表

赛托生物

(300583)

  

流通市值:27.42亿  总市值:27.94亿
流通股本:1.86亿   总股本:1.90亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金180,522,770.84605,873,475.96472,826,121.15328,861,563.01
  收到的税费返还26,090.83,226,298.426,008,155.22,952,789.18
  收到其他与经营活动有关的现金40,971,995.7870,173,853.0874,502,568.3268,114,536.9
  经营活动现金流入小计221,520,857.42679,273,627.46553,336,844.67399,928,889.09
  购买商品、接受劳务支付的现金88,893,572.56294,881,931.04280,228,955.55188,443,992.38
  支付给职工以及为职工支付的现金32,383,915.62113,107,757.4183,664,413.5556,656,372.07
  支付的各项税费24,094,918.4442,062,598.6423,869,256.7414,412,460.34
  支付其他与经营活动有关的现金45,401,470.6670,691,113.287,764,996.0177,734,441.58
  经营活动现金流出小计190,773,877.28520,743,400.29475,527,621.85337,247,266.37
  经营活动产生的现金流量净额30,746,980.14158,530,227.1777,809,222.8262,681,622.72
二、投资活动产生的现金流量:
  取得投资收益收到的现金-4,130,021.224,130,021.224,130,021.22
  处置固定资产、无形资产和其他长期资产收回的现金净额489,00041,62825,6207,500
  收到的其他与投资活动有关的现金--6,366,953.59-
  投资活动现金流入小计489,0004,171,649.2210,522,594.814,137,521.22
  购建固定资产、无形资产和其他长期资产支付的现金30,686,397.2779,651,345.4834,956,932.9824,210,984.82
  投资支付的现金-3,000,0003,000,000-
  投资活动现金流出小计30,686,397.2782,651,345.4837,956,932.9824,210,984.82
  投资活动产生的现金流量净额-30,197,397.27-78,479,696.26-27,434,338.17-20,073,463.6
三、筹资活动产生的现金流量:
  吸收投资收到的现金-1,000,000--
  其中:子公司吸收少数股东投资收到的现金-1,000,000--
  取得借款收到的现金210,733,769.7763,051,730455,240,232.3415,240,232.3
  收到其他与筹资活动有关的现金4,894,737.4336,000,00035,214,04035,770,950
  筹资活动现金流入小计215,628,507.13800,051,730490,454,272.3451,011,182.3
  偿还债务支付的现金237,165,876.55718,177,327.6464,940,712.77401,240,120.45
  分配股利、利润或偿付利息支付的现金6,617,682.4927,764,900.5622,661,868.7116,024,842.68
  支付其他与筹资活动有关的现金17,471,027.7725,045,934.7824,425,250.2622,550,592.86
  筹资活动现金流出小计261,254,586.81770,988,162.94512,027,831.74439,815,555.99
  筹资活动产生的现金流量净额-45,626,079.6829,063,567.06-21,573,559.4411,195,626.31
四、汇率变动对现金及现金等价物的影响-1,083,969.1-1,332,678.06-1,001,376.16-934,046.34
五、现金及现金等价物净增加额-46,160,465.91107,781,419.9127,799,949.0552,869,739.09
  加:期初现金及现金等价物余额263,271,140.93155,489,721.02155,489,721.02155,489,721.02
  期末现金及现金等价物余额217,110,675.02263,271,140.93183,289,670.07208,359,460.11
补充资料:
  净利润--84,680,814.44--59,836,360.14
  资产减值准备-53,073,813.02-27,993,162.86
  固定资产和投资性房地产折旧-158,259,853.7-79,148,062.53
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-158,259,853.7-79,148,062.53
  无形资产摊销-7,246,546.37-3,561,673.36
  长期待摊费用摊销-817,992.37-785,937.33
  处置固定资产、无形资产和其他长期资产的损失-824,300.99-162,577.53
  固定资产报废损失-483,203.03-517,806.54
  财务费用-30,360,293.6-16,440,407.35
  投资损失--6,489,808.78--4,091,379.24
  递延所得税-2,420,180.05-3,638,470.44
  其中:递延所得税资产减少-3,087,732.9-3,732,765.02
    递延所得税负债增加--667,552.85--94,294.58
  存货的减少-132,777,479.74-106,271,263.38
  经营性应收项目的减少--133,821,213.74--77,640,828.4
  经营性应付项目的增加--4,975,915.99--33,280,121.09
  现金的期末余额-263,271,140.93-208,359,460.11
  减:现金的期初余额-155,489,721.02-155,489,721.02
  现金及现金等价物的净增加额-107,781,419.91-52,869,739.09
公告日期2026-04-282026-04-282025-10-292025-08-26
审计意见(境内)标准无保留意见
TOP↑